메뉴 건너뛰기




Volumn 2, Issue 3, 2003, Pages 225-226

Overcoming resistance to imatinib by combining targeted agents

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; IMATINIB; LONAFARNIB; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRANSFERASE;

EID: 0642333844     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (36)

References (19)
  • 1
    • 0034670036 scopus 로고    scopus 로고
    • The molecular biology of chronic myeloid leukemia
    • Deininger, M. W., Goldman, J. M., and Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-3356, 2000.
    • (2000) Blood , vol.96 , pp. 3343-3356
    • Deininger, M.W.1    Goldman, J.M.2    Melo, J.V.3
  • 2
    • 0036139993 scopus 로고    scopus 로고
    • STI571: A paradigm of new agents for cancer therapeutics
    • Mauro, M. J., O'Dwyer, M., Heinrich, M. C., and Druker, B. J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol., 20: 325-334, 2002.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 325-334
    • Mauro, M.J.1    O'Dwyer, M.2    Heinrich, M.C.3    Druker, B.J.4
  • 3
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Fernandes Reese, S., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
    • (2001) N. Engl. J. Med. , vol.344 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3    Resta, D.J.4    Fernandes Reese, S.5    Ford, J.M.6    Capdeville, R.7    Talpaz, M.8
  • 5
    • 0035282735 scopus 로고    scopus 로고
    • Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
    • Reichert, A., Heisterkamp, N., Daley, G. Q., and Groffen, J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood, 97: 1399-1403, 2001.
    • (2001) Blood , vol.97 , pp. 1399-1403
    • Reichert, A.1    Heisterkamp, N.2    Daley, G.Q.3    Groffen, J.4
  • 6
    • 0035282901 scopus 로고    scopus 로고
    • Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
    • Peters, D. G., Hoover, R. R., Gerlach, M. J., Koh, E. Y., Zhang, H., Choe, K., Kirschmeier, P., Bishop, W. R., and Daley, G. Q. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood, 97: 1404-1412, 2001.
    • (2001) Blood , vol.97 , pp. 1404-1412
    • Peters, D.G.1    Hoover, R.R.2    Gerlach, M.J.3    Koh, E.Y.4    Zhang, H.5    Choe, K.6    Kirschmeier, P.7    Bishop, W.R.8    Daley, G.Q.9
  • 9
    • 0344611212 scopus 로고    scopus 로고
    • Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjuction with imatinib against Bcr-Abl-positive cells
    • Nakajima, A., Tauchi, T., Sumi, M., Bishop, W. R., and Ohyashiki, K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjuction with imatinib against Bcr-Abl-positive cells. Mol. Cancer Ther., 2: 219-224, 2003.
    • (2003) Mol. Cancer Ther. , vol.2 , pp. 219-224
    • Nakajima, A.1    Tauchi, T.2    Sumi, M.3    Bishop, W.R.4    Ohyashiki, K.5
  • 10
    • 0036683409 scopus 로고    scopus 로고
    • Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
    • Hoover, R. R., Mahon, F. X., Melo, J. V., and Daley, G. Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100: 1068-1071, 2002.
    • (2002) Blood , vol.100 , pp. 1068-1071
    • Hoover, R.R.1    Mahon, F.X.2    Melo, J.V.3    Daley, G.Q.4
  • 12
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Cold Spring Harbor
    • Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., and Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cells (Cold Spring Harbor), 2: 117-125, 2002.
    • (2002) Cancer Cells , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3    Gorre, M.E.4    Paquette, R.L.5    Kuriyan, J.6    Sawyers, C.L.7
  • 13
    • 0037199996 scopus 로고    scopus 로고
    • Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
    • Corbin, A. S., Buchdunger, E., Pascal, F., and Druker, B. J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem., 277: 32214-32219, 2002.
    • (2002) J. Biol. Chem. , vol.277 , pp. 32214-32219
    • Corbin, A.S.1    Buchdunger, E.2    Pascal, F.3    Druker, B.J.4
  • 14
    • 0038375012 scopus 로고    scopus 로고
    • Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
    • in press
    • Corbin, A. S., La Rosée, P., Stoffregen, E., Druker, B. J., and Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, in press, 2003.
    • (2003) Blood
    • Corbin, A.S.1    La Rosée, P.2    Stoffregen, E.3    Druker, B.J.4    Deininger, M.W.5
  • 15
    • 0038584950 scopus 로고    scopus 로고
    • Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): Results of a randomized Phase III study vs interferon-α + cytarabine
    • for the IRIS (International Randomized IFN vs STI571) Study Group
    • Larson, R. A. for the IRIS (International Randomized IFN vs STI571) Study Group. Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized Phase III study vs interferon-α + cytarabine. Blood, 100: 4a, 2002.
    • (2002) Blood , vol.100
    • Larson, R.A.1
  • 17
    • 0036090222 scopus 로고    scopus 로고
    • Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    • Graham, S. M., Jorgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., and Holyoake, T. L. Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99: 319-325, 2002.
    • (2002) Blood , vol.99 , pp. 319-325
    • Graham, S.M.1    Jorgensen, H.G.2    Allan, E.3    Pearson, C.4    Alcorn, M.J.5    Richmond, L.6    Holyoake, T.L.7
  • 18
    • 0032981812 scopus 로고    scopus 로고
    • Targeting farnesyltransferase: Is Ras relevant?
    • Prendergast, G. C., and Du, W. Targeting farnesyltransferase: is Ras relevant? Drug Resist. Update, 2: 81-84, 1999.
    • (1999) Drug Resist. Update , vol.2 , pp. 81-84
    • Prendergast, G.C.1    Du, W.2
  • 19
    • 0033016719 scopus 로고    scopus 로고
    • Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
    • Du, W., Lebowitz, P. F., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol., 19: 1831-1840, 1999.
    • (1999) Mol. Cell. Biol. , vol.19 , pp. 1831-1840
    • Du, W.1    Lebowitz, P.F.2    Prendergast, G.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.